Thyroglobulin Levels and Thyroglobulin Doubling Time Independently Predict a Positive 18F-FDG PET/CT Scan in Patients with Biochemical Recurrence of Differentiated Thyroid Carcinoma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2013 Mar 7

PMID 23463330

Citations 26

Authors

Luca Giovanella

Pierpaolo Trimboli

Frederik A Verburg

Giorgio Treglia

Arnoldo Piccardo

Luca Foppiani

Luca Ceriani

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the relationship between serum thyroglobulin (Tg) levels, Tg doubling time (Tg-DT) and the diagnostic performance of (18)F-FDG PET/CT in detecting recurrences of (131)I-negative differentiated thyroid carcinoma (DTC).

Methods: Included in the present study were 102 patients with DTC. All patients were treated by thyroid ablation (e.g. thyroidectomy and (131)I), and underwent (18)F-FDG PET/CT due to detectable Tg levels and negative conventional imaging. Consecutive serum Tg measurements performed before the (18)F-FDG PET/CT examination were used for Tg-DT calculation. The (18)F-FDG PET/CT results were assessed as true or false after histological and/or clinical follow-up.

Results: Serum Tg levels were higher in patients with a positive (18)F-FDG PET/CT scan (median 6.7 ng/mL, range 0.7-73.6 ng/mL) than in patients with a negative scan (median 1.8 ng/mL, range 0.5-4.9 ng/mL; P < 0.001). In 43 (88 %) of 49 patients with a true-positive (18)F-FDG PET/CT scan, the Tg levels were >5.5 ng/mL, and in 31 (74 %) of 42 patients with a true-negative (18)F-FDG PET/CT scan, the Tg levels were ≤5.5 ng/mL. A Tg-DT of <1 year was found in 46 of 49 patients (94 %) with a true-positive (18)F-FDG PET/CT scan, and 40 of 42 patients (95 %) with a true-negative scan had a stable or increased Tg-DT. Moreover, combining Tg levels and Tg-DT as selection criteria correctly distinguished between patients with a positive and a negative scan (P<0.0001).

Conclusion: The accuracy of (18)F-FDG PET/CT significantly improves when the serum Tg level is above 5.5 ng/mL during levothyroxine treatment or when the Tg-DT is less than 1 year, independent of the absolute value.

Citing Articles

The Role of Positron Emission Tomography/Computed Tomography in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives.

Panagiotidis E, Zhang-Yin J J Clin Med. 2024; 13(22).

PMID: 39598062 PMC: 11595340. DOI: 10.3390/jcm13226918.

Role of [F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma.

Zajkowska K, Cegla P, Dedecjus M Cancer Imaging. 2024; 24(1):147.

PMID: 39468677 PMC: 11514821. DOI: 10.1186/s40644-024-00791-8.

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer.

Petranovic Ovcaricek P, Campenni A, de Keizer B, Deandreis D, Kreissl M, Vrachimis A Cancers (Basel). 2023; 15(17).

PMID: 37686566 PMC: 10486510. DOI: 10.3390/cancers15174290.

Molecular Imaging and Theragnostics of Thyroid Cancers.

Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P Cancers (Basel). 2022; 14(5).

PMID: 35267580 PMC: 8909041. DOI: 10.3390/cancers14051272.

The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis.

Giovanella L, Garo M, Albano D, Gorges R, Ceriani L Endocr Connect. 2022; 11(4).

PMID: 35245206 PMC: 9066573. DOI: 10.1530/EC-21-0648.

References

Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A . Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?. Thyroid. 2009; 20(1):15-23. DOI: 10.1089/thy.2008.0416. View

Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S . F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009; 34(11):756-61. DOI: 10.1097/RLU.0b013e3181b7d95c. View

Bidart J, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N . Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999; 45(10):1695-707. View

Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg F . Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2011; 34(5):626-31. DOI: 10.1002/hed.21791. View

Freudenberg L, Antoch G, Frilling A, Jentzen W, Rosenbaum S, Kuhl H . Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008; 35(5):950-7. DOI: 10.1007/s00259-007-0634-8. View

Leboulleux S, Schroeder P, Schlumberger M, Ladenson P . The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007; 3(2):112-21. DOI: 10.1038/ncpendmet0402. View

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787-803. DOI: 10.1530/eje.1.02158. View

Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H . Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1998; 24(11):1342-8. DOI: 10.1007/s002590050158. View

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

10.

Miller M, Chen Q, Elashoff D, Abemayor E, St John M . Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2010; 33(4):562-5. DOI: 10.1002/hed.21492. View

11.

Giovanella L, Keller F, Ceriani L, Tozzoli R . Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2009; 47(8):952-4. DOI: 10.1515/CCLM.2009.230. View

12.

Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y . Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011; 21(7):707-16. DOI: 10.1089/thy.2010.0355. View

13.

Fatourechi V, Hay I . Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000; 30(2):107-14. DOI: 10.1053/nm.2000.4600. View

14.

Wong H, Wong K, Yau T, Tang V, Leung R, Chiu J . Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?. Ann Surg Oncol. 2012; 19(11):3479-85. PMC: 3442160. DOI: 10.1245/s10434-012-2391-6. View

15.

Shammas A, Degirmenci B, Mountz J, McCook B, Branstetter B, Bencherif B . 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007; 48(2):221-6. View

16.

Freudenberg L, Frilling A, Kuhl H, Muller S, Jentzen W, Bockisch A . Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol. 2007; 17(12):3139-47. DOI: 10.1007/s00330-007-0682-2. View

17.

Schluter B, Bohuslavizki K, Beyer W, Plotkin M, Buchert R, Clausen M . Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001; 42(1):71-6. View

18.

Iagaru A, Kalinyak J, McDougall I . F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007; 32(9):690-5. DOI: 10.1097/RLU.0b013e318125037a. View

19.

Treglia G, Muoio B, Giovanella L, Salvatori M . The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2012; 270(6):1783-7. DOI: 10.1007/s00405-012-2205-2. View

20.

Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H . Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010; 20(5):527-33. DOI: 10.1089/thy.2009.0342. View